

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 February 2022 (17.02.2022)



(10) International Publication Number
WO 2022/035828 A1

(51) International Patent Classification:

A61P 19/06 (2006.01) A61K 47/60 (2017.01)
A61K 38/44 (2006.01) A61K 31/505 (2006.01)

(21) International Application Number:

PCT/US2021/045350

(22) International Filing Date:

10 August 2021 (10.08.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/063,826 10 August 2020 (10.08.2020) US
63/148,982 12 February 2021 (12.02.2021) US

(71) Applicant: **HORIZON THERAPEUTICS IRELAND DAC** [IE/IE]; Connaught House, 1st Floor, 1 Burlington Road, Dublin 4, D04 C5Y6 (IE).

(72) Inventors: **PELOSO, Paul**; 1 Horizon Way, Deerfield, Illinois 60015 (US). **LAMOREAUX, Brian**; 1 Horizon Way, Deerfield, Illinois 60015 (US). **VERMA, Swarnendra**; 1 Horizon Way, Deerfield, Illinois 60015 (US).

(74) Agent: **GREER, Stephanie**; Global Patent Group, LLC, P.O. Box 1636, Canóvanas, 00729 (PR).


(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: METHODS OF TREATING GOUT



(57) Abstract: The disclosure provides methods of treating gout in patients comprising administering a PEGylated uricase in a shortened infusion period less than 120 minutes and a shortened infusion volume of less than 250 mL. Also provided are methods of treating gout in patients comprising co-administering a PEGylated uricase and methotrexate (MTX). Also provided are methods of reducing immunogenicity of a PEGylated uricase and prolonging the urate lowering effect comprising co-administration of the PEGylated uricase and MTX.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*